B9A Stock Overview
Develops biological drugs for patients with disorders of the central nervous system in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 18.86 |
| 52 Week High | SEK 24.84 |
| 52 Week Low | SEK 11.94 |
| Beta | -0.27 |
| 1 Month Change | 19.07% |
| 3 Month Change | 32.35% |
| 1 Year Change | -18.78% |
| 3 Year Change | 62.59% |
| 5 Year Change | 110.84% |
| Change since IPO | 141.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| B9A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 25.6% | -3.5% | -2.0% |
| 1Y | -18.8% | -14.7% | 6.9% |
Return vs Industry: B9A underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: B9A underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| B9A volatility | |
|---|---|
| B9A Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B9A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: B9A's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 104 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.
BioArctic AB (publ) Fundamentals Summary
| B9A fundamental statistics | |
|---|---|
| Market cap | €1.63b |
| Earnings (TTM) | -€20.24m |
| Revenue (TTM) | €14.53m |
112.5x
P/S Ratio-80.8x
P/E RatioIs B9A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B9A income statement (TTM) | |
|---|---|
| Revenue | SEK 167.14m |
| Cost of Revenue | SEK 90.50m |
| Gross Profit | SEK 76.64m |
| Other Expenses | SEK 309.50m |
| Earnings | -SEK 232.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -2.63 |
| Gross Margin | 45.85% |
| Net Profit Margin | -139.32% |
| Debt/Equity Ratio | 0% |
How did B9A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 09:07 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioArctic AB (publ) is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Patrik Ling | DNB Markets |
| Rajan Sharma | Goldman Sachs |